192 related articles for article (PubMed ID: 17348010)
1. A recombinant allosteric lectin antagonist of HIV-1 envelope gp120 interactions.
McFadden K; Cocklin S; Gopi H; Baxter S; Ajith S; Mahmood N; Shattock R; Chaiken I
Proteins; 2007 May; 67(3):617-29. PubMed ID: 17348010
[TBL] [Abstract][Full Text] [Related]
2. Mode of action for linear peptide inhibitors of HIV-1 gp120 interactions.
Biorn AC; Cocklin S; Madani N; Si Z; Ivanovic T; Samanen J; Van Ryk DI; Pantophlet R; Burton DR; Freire E; Sodroski J; Chaiken IM
Biochemistry; 2004 Feb; 43(7):1928-38. PubMed ID: 14967033
[TBL] [Abstract][Full Text] [Related]
3. Potent inhibition of HIV-1 fusion by cyanovirin-N requires only a single high affinity carbohydrate binding site: characterization of low affinity carbohydrate binding site knockout mutants.
Chang LC; Bewley CA
J Mol Biol; 2002 Apr; 318(1):1-8. PubMed ID: 12054763
[TBL] [Abstract][Full Text] [Related]
4. Identification and characterization of peptides that bind to cyanovirin-N, a potent human immunodeficiency virus-inactivating protein.
Han Z; Simpson JT; Fivash MJ; Fisher R; Mori T
Peptides; 2004 Apr; 25(4):551-61. PubMed ID: 15165709
[TBL] [Abstract][Full Text] [Related]
5. Restricted HIV-1 Env glycan engagement by lectin-reengineered DAVEI protein chimera is sufficient for lytic inactivation of the virus.
Parajuli B; Acharya K; Bach HC; Parajuli B; Zhang S; Smith AB; Abrams CF; Chaiken I
Biochem J; 2018 Mar; 475(5):931-957. PubMed ID: 29343613
[TBL] [Abstract][Full Text] [Related]
6. Critical role of Arg59 in the high-affinity gp120-binding region of CD4 for human immunodeficiency virus type 1 infection.
Fontenot D; Jones JK; Hossain MM; Nehete PN; Vela EM; Dwyer VA; Jagannadha Sastry K
Virology; 2007 Jun; 363(1):69-78. PubMed ID: 17320923
[TBL] [Abstract][Full Text] [Related]
7. Dissecting carbohydrate-Cyanovirin-N binding by structure-guided mutagenesis: functional implications for viral entry inhibition.
Barrientos LG; Matei E; Lasala F; Delgado R; Gronenborn AM
Protein Eng Des Sel; 2006 Dec; 19(12):525-35. PubMed ID: 17012344
[TBL] [Abstract][Full Text] [Related]
8. The recognition of chimeras of rat and human CD4 by HIV-1 gp120 and by monoclonal antibodies.
Davis SJ; James WS; Schockmel GA; Simon JH; Somoza C
Philos Trans R Soc Lond B Biol Sci; 1993 Oct; 342(1299):75-81. PubMed ID: 7904351
[TBL] [Abstract][Full Text] [Related]
9. The potent anti-HIV protein cyanovirin-N contains two novel carbohydrate binding sites that selectively bind to Man(8) D1D3 and Man(9) with nanomolar affinity: implications for binding to the HIV envelope protein gp120.
Bewley CA; Otero-Quintero S
J Am Chem Soc; 2001 May; 123(17):3892-902. PubMed ID: 11457139
[TBL] [Abstract][Full Text] [Related]
10. Selection and characterization of an HIV-1 gp120-binding affibody ligand.
Wikman M; Rowcliffe E; Friedman M; Henning P; Lindholm L; Olofsson S; Ståhl S
Biotechnol Appl Biochem; 2006 Sep; 45(Pt 2):93-105. PubMed ID: 16712522
[TBL] [Abstract][Full Text] [Related]
11. A monovalent mutant of cyanovirin-N provides insight into the role of multiple interactions with gp120 for antiviral activity.
Fromme R; Katiliene Z; Giomarelli B; Bogani F; Mc Mahon J; Mori T; Fromme P; Ghirlanda G
Biochemistry; 2007 Aug; 46(32):9199-207. PubMed ID: 17636873
[TBL] [Abstract][Full Text] [Related]
12. Mapping resistance to the CCR5 co-receptor antagonist vicriviroc using heterologous chimeric HIV-1 envelope genes reveals key determinants in the C2-V5 domain of gp120.
Ogert RA; Wojcik L; Buontempo C; Ba L; Buontempo P; Ralston R; Strizki J; Howe JA
Virology; 2008 Apr; 373(2):387-99. PubMed ID: 18190945
[TBL] [Abstract][Full Text] [Related]
13. HIV infection is blocked in vitro by recombinant soluble CD4.
Fisher RA; Bertonis JM; Meier W; Johnson VA; Costopoulos DS; Liu T; Tizard R; Walker BD; Hirsch MS; Schooley RT
Nature; 1988 Jan; 331(6151):76-8. PubMed ID: 2829022
[TBL] [Abstract][Full Text] [Related]
14. The HIV-inactivating protein, cyanovirin-N, does not block gp120-mediated virus-to-cell binding.
Mariner JM; McMahon JB; O'Keefe BR; Nagashima K; Boyd MR
Biochem Biophys Res Commun; 1998 Jul; 248(3):841-5. PubMed ID: 9704015
[TBL] [Abstract][Full Text] [Related]
15. The antiviral lectin cyanovirin-N: probing multivalency and glycan recognition through experimental and computational approaches.
Woodrum BW; Maxwell JD; Bolia A; Ozkan SB; Ghirlanda G
Biochem Soc Trans; 2013 Oct; 41(5):1170-6. PubMed ID: 24059504
[TBL] [Abstract][Full Text] [Related]
16. A peptidomimetic HIV-entry inhibitor directed against the CD4 binding site of the viral glycoprotein gp120.
Neffe AT; Meyer B
Angew Chem Int Ed Engl; 2004 May; 43(22):2937-40. PubMed ID: 15170309
[No Abstract] [Full Text] [Related]
17. Inhibition of V3-specific cleavage of recombinant HIV-1 gp120 produced in Chinese hamster ovary cells.
Du SX; Xu L; Viswanathan S; Whalen RG
Protein Expr Purif; 2008 Jun; 59(2):223-31. PubMed ID: 18406166
[TBL] [Abstract][Full Text] [Related]
18. Solution structure of a cyanovirin-N:Man alpha 1-2Man alpha complex: structural basis for high-affinity carbohydrate-mediated binding to gp120.
Bewley CA
Structure; 2001 Oct; 9(10):931-40. PubMed ID: 11591348
[TBL] [Abstract][Full Text] [Related]
19. Glycan deletions in the HIV-1 gp120 V1/V2 domain compromise viral infectivity, sensitize the mutant virus strains to carbohydrate-binding agents and represent a specific target for therapeutic intervention.
Auwerx J; François KO; Covens K; Van Laethem K; Balzarini J
Virology; 2008 Dec; 382(1):10-9. PubMed ID: 18930512
[TBL] [Abstract][Full Text] [Related]
20. Protein minimization of the gp120 binding region of human CD4.
Sharma D; Balamurali MM; Chakraborty K; Kumaran S; Jeganathan S; Rashid U; Ingallinella P; Varadarajan R
Biochemistry; 2005 Dec; 44(49):16192-202. PubMed ID: 16331979
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
